 By Beth Senko, CFA NASDAQ:CASI READ THE FULL CASI RESEARCH REPORT CASI Pharmaceuticals NASDAQ:CASI signaled a shift in its business strategy in March focusing its efforts on its hematology franchise and deemphasizing its ANDA portfolio. This change scales back CASIs initial broad-reaching goal to be the leading provider of high quality proprietary, licensed and ANDA pharmaceuticals to the 